Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT307 in advanced ovarian cancer
NCT06453057Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of GT307 in ovarian cancer, sponsored by Grit Biotechnology. Primary endpoints: Adverse Events at 3 years and Objective Response Rate at 3 years. Started Jul 2024; status: recruiting.
02
Drugs
GT307
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06453057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453057.